scholarly journals Evaluation of Clinical and Immunopathological Features of Different Infective Doses ofTrypanosoma cruziin Dogs during the Acute Phase

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Israel A. Quijano-Hernández ◽  
Alejandro Castro-Barcena ◽  
Esteban Aparicio-Burgos ◽  
Marco A. Barbosa-Mireles ◽  
Julio V. Cruz-Chan ◽  
...  
Keyword(s):  
Latin America ◽  
Trypanosoma Cruzi ◽  
Acute Phase ◽  
Antibody Production ◽  
Cardiac Arrhythmias ◽  
Similar Pattern ◽  
Low Dose ◽  
Pathologic Lesions ◽  
Electrocardiographic Parameters ◽  
High Parasite

Infection withTrypanosoma cruziis a major risk in Latin America, and dogs are believed to be good models for evaluating Chagas disease. Here, we evaluated the clinical and immunopathological alterations developed by mongrel dogs experimentally infected with different infective doses (2,000, 20,000, and 200,000 metacyclic trypomastigotes of Sylvio X10/4 strain kg−1via intraperitoneal). Clinical and electrocardiographic parameters, as well as antibody production and pathologic lesions were evaluated. All three doses of this strain ofT. cruziinduced a similar pattern of infection characterized by cardiac arrhythmias and severe and diffuse myocarditis. Specific anti-T. cruziIgG indicated seroconversion by day 14 after infection, and IgG levels increased during the period of evaluation. Mortality was observed only in dogs infected with the medium or high parasite doses, but not in the group infected with a low dose of 2,000 parasites kg-1. Infection with a low dose of parasites provides an excellent nonlethal model to evaluate the immunopathology of the acute disease in dogs infected with the Sylvio X10/4 strain ofT. cruzi.

scholarly journals Evolution of anti-Trypanosoma cruzi antibody production in patients with chronic Chagas disease: Correlation between antibody titers and development of cardiac disease severity

2017 ◽  
Vol 11 (7) ◽  
pp. e0005796 ◽  
Author(s):  
Ingebourg Georg ◽  
Alejandro Marcel Hasslocher-Moreno ◽  
Sergio Salles Xavier ◽  
Marcelo Teixeira de Holanda ◽  
Eric Henrique Roma ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Disease Severity ◽  
Chagas Disease ◽  
Antibody Production ◽  
Cardiac Disease ◽  
Antibody Titers ◽  
Chronic Chagas Disease

Complications Associated with Digoxin Therapy in Low-Birth Weight Infants

PEDIATRICS ◽  
1982 ◽  
Vol 69 (4) ◽  
pp. 463-465
Author(s):  
Gregory L. Johnson ◽  
Nirmala S. Desai ◽  
Thomas H. Pauly ◽  
M. Douglas Cunningham
Keyword(s):  
Birth Weight ◽  
Low Birth Weight ◽  
Cardiac Arrhythmias ◽  
Low Dose ◽  
Ductus Arteriosus ◽  
Low Birth Weight Infants ◽  
Feeding Difficulties ◽  
Frequent Episodes ◽  
Seriously Ill ◽  
Digoxin Therapy

Eighteen infants, each weighing less than 1,500 gm, were treated with low dose digoxin therapy for patent ductus arteriosus and signs of circulatory congestion. Nine of the 18 developed one or more signs of clinical deterioration felt to be related to digoxin therapy: eight infants experienced frequent episodes of bradycardia, six had cardiac arrhythmias, and six experienced feeding difficulties. All signs disappeared when digoxin therapy was discontinued. Digoxin, even in relatively low dosages, can have deleterious complications in seriously ill low-birth-weight infants. Alternatives to digoxin in this patient population should be considered before institution of digoxin therapy.

scholarly journals The anticancer drug tamoxifen is active against Trypanosoma cruzi in vitro but ineffective in the treatment of the acute phase of Chagas disease in mice

2010 ◽  
Vol 105 (7) ◽  
pp. 945-948 ◽  
Author(s):  
Danilo Ciccone Miguel ◽  
Marcela Lencine Ferraz ◽  
Rosana de Oliveira Alves ◽  
Jenicer KU Yokoyama-Yasunaka ◽  
Ana Claudia Torrecilhas ◽  
...  
Keyword(s):  
Trypanosoma Cruzi ◽  
Chagas Disease ◽  
Anticancer Drug ◽  
Acute Phase

scholarly journals Population Polymorphism of Trypanosoma cruzi in Latin America indicated by Proteome analysis and by in vitro amastigote proliferation

2006 ◽  
Vol 34 (4) ◽  
pp. 167-174
Author(s):  
JIAN-BING MU ◽  
TOSHIO SONE ◽  
TETSUO YANAGI ◽  
ISAO TADA ◽  
MIHOKO KIKUCHI ◽  
...  
Keyword(s):  
Latin America ◽  
Trypanosoma Cruzi ◽  
Proteome Analysis ◽  
Population Polymorphism

Combined treatment with benznidazole and allopurinol in mice infected with a virulentTrypanosoma cruziisolate from Nicaragua

Parasitology ◽  
2013 ◽  
Vol 140 (10) ◽  
pp. 1225-1233 ◽  
Author(s):  
NOELIA L. GROSSO ◽  
MICAELA LOPEZ ALARCON ◽  
JAQUELINE BUA ◽  
SUSANA A. LAUCELLA ◽  
ADELINA RIARTE ◽  
...  
Keyword(s):  
Survival Rate ◽  
Trypanosoma Cruzi ◽  
Endemic Area ◽  
Low Dose ◽  
Combined Treatment ◽  
Chronic Phase ◽  
Experimental Models ◽  
Specific Antibodies ◽  
Histopathological Studies ◽  
Virulent Parasite

SUMMARYWe evaluated the effect of chemotherapy with a sequential combined treatment of a low dose of benznidazole and allopurinol, in different schedules of administration, in experimental models of acute and chronicTrypanosoma cruziinfection. Mice were infected with NicaraguaT. cruziisolate, a virulent parasite from an endemic area of Nicaragua, genotyped asTcI (Grossoet al. 2010). We assessed survival rate, IgG levels, histopathological studies and quantified parasitaemia. A 15% survival rate was recorded in untreated mice during the acute phase ofT. cruziinfection. Allopurinol administered immediately after benznidazole treatment was able to reduce parasitaemia and attenuate tissue damage by reducing inflammation.Trypanosoma cruzi-specific antibodies also decreased in 40–50% of the treated mice. The addition of allopurinol during the chronic phase showed the highest beneficial effect, not only by reducing parasitaemia but also by lowering the degree of inflammation and fibrosis.

Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review

2020 ◽  
pp. archdischild-2019-318245
Author(s):  
Ming-Hsiu Chiang ◽  
Hsingjin Eugene Liu ◽  
Jinn-Li Wang
Keyword(s):  
Systematic Review ◽  
Kawasaki Disease ◽  
Acute Phase ◽  
Low Dose ◽  
Meta Analysis ◽  
Length Of Hospital Stay ◽  
High Dose ◽  
Cochrane Central Register ◽  
Factors Affecting ◽  
Standard Mean Difference

ObjectiveTo compare the efficacy of low-dose or no aspirin with conventional high-dose aspirin for the initial treatment in the acute-phase of Kawasaki disease (KD).DesignA meta-analysis and systematic review of randomised control trials and cohort studies.MethodsAll available articles that compared different dosage of aspirin in the acute-phase of KD published until 20 September 2019 were included from the databases of PubMed, Embase and Cochrane Central Register of Controlled Trials Central without language restrictions. Extracted data from eligible studies were reviewed by two authors independently and analysed by using RStudio software.ResultsNine cohorts with a total of 12 182 children were enrolled. We found that low-dose (3–5 mg/kg/day) or no aspirin in the acute-phase KD was associated with reducing the risk of coronary artery lesions (CALs, OR=0.81, 95% CI 0.69 to 0.95). No differences were observed in intravenous immunoglobulin resistance, length of hospital stay and fever days after admission (OR=1.35, 95% CI 0.91 to 1.98; standard mean difference (SMD)=0.17, 95% CI −1.07 to 1.4; SMD=0.3, 95% CI −1.51 to 2.11) in the low-dose/no aspirin subgroup compared with the high-dose (≥30 mg/kg/day) aspirin subgroup. We did not identify any potential factors affecting the homogeneity of CAL risk as well as clinical important effects in all included studies.ConclusionsPrescribing low-dose or no aspirin in the acute-phase of KD might be associated with a decreased incidence of CAL. However, additional well-designed prospective trials are required to support the theory.

scholarly journals Chagasic meningoencephalitis in the immunodeficient

1998 ◽  
Vol 56 (1) ◽  
pp. 93-97 ◽  
Author(s):  
LAZO JAVIER ◽  
ANTONIO CARLOS OLIVEIRA MENESES ◽  
ADEMIR ROCHA ◽  
MARCELO SIMÃO FERREIRA ◽  
JAIME OLAVO MARQUEZ ◽  
...  
Keyword(s):  
Natural History ◽  
Trypanosoma Cruzi ◽  
Chagas Disease ◽  
Acute Phase ◽  
Brain Pathology ◽  
History Of ◽  
The Brain

Based on their own experience and on the literature, the authors compare the brain pathology due to HIV+ associated Trypanosoma cruzi reactived infection to that described for the natural history of the Chagas' disease (CD). The peculiar focal necrotizing chagasic meningoencephalitis (MECNF) which appears only in immunedeficient chagasics, especially when the deficiency is due HIV is a safe criterion for reactivation of CD. MECNF morphologic findings are unlike to those found either for some cases of acute phase CD or for chronic nervous form of CD.

scholarly journals The remarkable pioneering contribution of Gaspar Vianna to the study of the neuropathology of Chagas disease

2018 ◽  
Vol 76 (12) ◽  
pp. 853-856
Author(s):  
José Eymard Homem Pittella
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Life Cycle ◽  
Trypanosoma Cruzi ◽  
Chagas Disease ◽  
Acute Phase ◽  
Central Nervous System Involvement ◽  
System Involvement

ABSTRACT Gaspar Vianna is considered one of the great names in Medicine and Science in Brazil. Yet, little prominence has been given to his studies in Neuropathology. He was the first to describe, in 1911, the histopathology and pathogenesis of chagasic encephalitis in the acute phase of Chagas disease, as well as the intracellular life cycle of Trypanosoma cruzi. Over 100 years have elapsed and Gaspar Vianna's pioneering study remains an example of a meticulous and still up-to-date description of central nervous system involvement in the acute phase of Chagas disease.

Sign in / Sign up

Export Citation Format

Share Document